Search

Search Constraints

You searched for: Author/Creator Mou, Benjamin

Search Results

3. 2: Population Based Phase II Trial of Stereotactic Ablative Radiotherapy (SABR) for Up to Five Oligometastases: Preliminary Results of the SABR-5 Trial. (October 2021)

4. 36: Progression-Free Survival and Local Control Following Stereotactic Ablative Radiotherapy for Up to Five Oligometastases: An Analysis from the Population-Based Phase II SABR-5 Trial. (September 2022)

5. 65: Predictors of Early Polymetastatic Relapse Following Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases: A Secondary Analysis of the Phase II SABR-5 Trial. (September 2022)

6. CMET-31. WHOLE BRAIN RADIOTHERAPY VERSUS STEREOTACTIC RADIOSURGERY IN POOR-PROGNOSIS PATIENTS WITH 1 – 10 BRAIN METASTASES: A RANDOMIZED FEASIBILITY STUDY. (11th November 2019)

7. Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? a secondary analysis of the population-based phase II SABR-5 trial. (May 2023)